HC Wainwright Reaffirms Buy Rating for Savara (NASDAQ:SVRA)

Savara (NASDAQ:SVRA)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $6.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 106.19% from the company’s previous close. HC Wainwright also issued estimates for Savara’s Q1 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.11) EPS.

Other analysts have also issued reports about the stock. Wells Fargo & Company assumed coverage on shares of Savara in a research report on Friday, December 20th. They set an “overweight” rating and a $8.00 price target for the company. JMP Securities restated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Savara presently has an average rating of “Moderate Buy” and a consensus target price of $8.83.

Savara Price Performance

Shares of SVRA stock opened at $2.91 on Friday. The stock has a market capitalization of $499.41 million, a price-to-earnings ratio of -6.77 and a beta of 0.60. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara has a twelve month low of $2.26 and a twelve month high of $5.34. The stock has a fifty day simple moving average of $2.72 and a two-hundred day simple moving average of $3.26.

Savara (NASDAQ:SVRA) last announced its earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The business had revenue of $0.27 million during the quarter. On average, analysts predict that Savara will post -0.45 EPS for the current fiscal year.

Institutional Trading of Savara

A number of hedge funds and other institutional investors have recently made changes to their positions in SVRA. The Manufacturers Life Insurance Company raised its stake in shares of Savara by 9.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company’s stock valued at $191,000 after acquiring an additional 3,706 shares during the period. Altium Capital Management LLC raised its position in Savara by 0.3% in the fourth quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company’s stock valued at $4,848,000 after purchasing an additional 4,000 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock worth $112,000 after purchasing an additional 4,732 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Savara by 13.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company’s stock worth $135,000 after buying an additional 5,236 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Savara by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company’s stock valued at $441,000 after buying an additional 5,450 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.